Previous Article | Next Article 
Journal of Virology, July 2001, p. 6537-6546, Vol. 75, No. 14
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.14.6537-6546.2001
Replication of Phenotypically Mixed Human
Immunodeficiency Virus Type 1 Virions Containing Catalytically Active
and Catalytically Inactive Reverse Transcriptase
John G.
Julias,
Andrea L.
Ferris,
Paul L.
Boyer, and
Stephen H.
Hughes*
HIV-Drug Resistance Program, NCI-Frederick,
Frederick, Maryland 21702-1201
Received 5 February 2001/Accepted 25 April 2001
 |
ABSTRACT |
The amount of excess polymerase and RNase H activity in human
immunodeficiency virus type 1 virions was measured by using vectors
that undergo a single round of replication. Vectors containing wild-type reverse transcriptase (RT), vectors encoding the D110E mutation to inactivate polymerase, and vectors encoding mutations D443A
and E478Q to inactivate RNase H were constructed. 293 cells were
cotransfected with different proportions of plasmids encoding these
vectors to generate phenotypically mixed virions. The resulting viruses
were used to infect human osteosarcoma cells, and the relative
infectivity of the viruses was determined by measuring transduction of
the murine cell surface marker CD24, which is encoded by the vectors.
The results indicated that there is an excess of both polymerase and
RNase H activities in virions. Viral replication was reduced to 42% of
wild-type levels in virions with where half of the RT molecules were
predicted to be catalytically active but dropped to 3% of wild-type
levels when 25% of the RT molecules were active. However, reducing
RNase H activity had a lesser effect on viral replication. As expected,
based on previous work with murine leukemia virus, there was relatively
inefficient virus replication when the RNase H and polymerase
activities were encoded on separate vectors (D110E plus E478Q and D110E
plus D443A). To determine how virus replication failed when polymerase
and RNase H activities were reduced, reverse transcription
intermediates were measured in vector-infected cells by using
quantitative real-time PCR. The results indicated that using the D11OE
mutation to reduce the amount of active polymerase reduced the number
of reverse transcripts that were initiated and also reduced the amounts
of products from the late stages of reverse transcription. If the E478Q
mutation was used to reduce RNase H activity, the number of reverse
transcripts that were initiated was reduced; there was also a strong
effect on minus-strand transfer.
 |
INTRODUCTION |
The viral enzyme reverse
transcriptase (RT) converts the single-stranded genomic RNA found in
retroviruses into double-stranded DNA. RT contains two enzymatic
activities that collaborate in this conversion: a DNA polymerase that
can copy either an RNA or a DNA template, and RNase H, which cleaves
RNA if (and only if) it is part of an RNA-DNA hybrid (see references
6, 25, and 66 for reviews). Both the polymerase and RNase
H activities are necessary for retroviral replication; mutations that
block RNase H activity also block virus replication (47, 49, 56, 61). RNase H activity is required during several steps of
reverse transcription. RNase H degradation is required for the
first-strand transfer reaction and generates the RNA primer for
plus-strand DNA synthesis. RNase H also removes the RNA primers used to
initiate plus- and minus-strand DNA synthesis (15, 18, 37, 38, 44-46, 51, 58, 62).
Human immunodeficiency virus type 1 (HIV-1) RT is a heterodimeric
protein; the two subunits are p66 and p51 (10). The p66 subunit contains 560 amino acids, and the p51 subunit is composed of
the same sequence as the first 440 amino acids of the p66 subunit. Based on the crystal structure, the polymerase domain of HIV-1 RT has
been likened to a right hand composed of fingers, palm, thumb, and
connection subdomains (31). Although the folding within
each of these subdomains is similar in the two subunits, the overall
spatial arrangement of the subdomains differs between the subunits
(27, 31). The polymerase and RNase H activities of RT
reside on the p66 subunit. A triad of aspartic acids residues (positions 110, 185, and 186) forms the polymerase active site that is
located in the p66 palm subdomain (27, 31). Although the
p51 subunit contains the same three aspartic acid residues, the p51
subunit does not directly contribute to the polymerase activity of RT
(33). The RNase H domain is primarily derived from the
15-kDa segment that is present only in the p66 subunit; p51 lacks an
RNase H domain (6). Crystallographic data show that the
RNase H active site is positioned approximately 17 nucleotides from the
polymerase active site; this distance is supported by biochemical
experiments (16, 19, 27, 43, 67).
The HIV-1 RT RNase H domain and the Escherichia coli RNase H
are related in structure and activity. The polypeptides chains share
24% sequence identity and fold into similar structures (29, 68). There is a strict conservation of the amino acids that comprise the RNase H active site. The active-site amino acid residues D443, E478, D498, and D549 of HIV-1 RT correspond to amino acids D10,
E48, D70, and D134 of E. coli RNase H (8, 25).
Mutations at any of these amino acids profoundly affect RNase H
activity and block virus replication. The degradation of the viral RNA by RNase H is not sequence specific, and a range of different-size RNase H cleavage products are generated. However, the RNase H cleavages
that generate the polypurine tract (ppt) primer and the cleavages that
remove the tRNA and ppt primers are site specific. In HIV-1
replication, the ppt primer is completely removed and the tRNA primer
is cleaved one nucleotide from the RNA/DNA junction (44, 45, 52,
65). The generation (and removal) of the ppt primer must be very
specific to ensure the proper synthesis of the left end of unintegrated
viral DNA; removal of the tRNA primer defines the right end of viral DNA.
Although RT can cleave an RNA template during polymerization, the
enzyme's two activities (polymerization and RNase H cleavage) can
function independently (9). However, both the structure of
RT and the biochemical behavior of wild-type and mutant enzymes show
that while the two enzymatic activities of RT are not strictly coupled,
the two domains (polymerase and RNase H) are interdependent in their
interactions with nucleic acid substrates. The degree of
interdependence of polymerase and RNase H domains is somewhat different
for different RTs. In the case of murine leukemia virus (MLV) RT, the
separately expressed RNase H and polymerase domains retain high levels
of enzymatic activity (32, 34, 57). However, with HIV-1
RT, the separately expressed domains have little activity. The lack of
activity of the separate RNase H domain of HIV-1 RT appears to be due
to weak binding of the substrate. When combined with a purified HIV-1
polymerase domain, the isolated HIV-1 RNase H domain regains activity
(24, 53). In addition, introducing a substrate-binding
element from E. coli RNase H into the isolated RNase H
domain of HIV-1 RT also restores enzymatic activity (30, 54).
The polymerase and RNase H activities of MLV RT can complement
inefficiently in vivo when present on separate RT molecules, demonstrating that the two enzymatic activities can act independently to successfully complete the synthesis of viral DNA (60).
Various MLV RNase H mutants were tested for the ability to complement RTs lacking polymerase activity. Some RNase H mutants failed to complement, suggesting that these RNase H mutations may also affect the
polymerase activity of RT (60). In support of this idea, some RNase H mutations of HIV-1 RT appear to affect the polymerase activity; mutations at position 478 have been reported to affect the in
vitro polymerase activity of RT (12, 13, 40, 63). This
mutation did not affect the initiation of reverse transcription in
vitro, suggesting that DNA synthesis was impaired at the level of
elongation (26).
Retroviral virions each contain approximately 50 to 100 molecules of
RT. There are approximately 2,000 molecules of Gag in a virion
(55; see also reference 6 for a review). The
ratio of Gag to Gag-Pol is about 20 to 1 (21, 28, 41).
This means that there are about 100 Gag-Pol molecules per virion. For
retroviruses, like HIV-1, in which the RT is a dimer, the number of RT
molecules in a virion should be approximately 50. This is a relatively
large number, and it is possible that there is an excess of polymerase activity, of RNase H activity, or of both. In support of this idea,
HIV-2 RT has, in an in vitro assay, approximately 10% of the RNase H
activity of HIV-1 RT (50). HIV-2 replicates reasonably well, which suggests the possibility that HIV-1 virions contain excess
RNase H activity. In vitro, HIV-1 RT is not a strongly processive
polymerase. HIV-1 RT dissociates from its primer-template frequently,
suggesting that viral DNA is synthesized in relatively short segments.
The relatively low processivity of RT might be the reason that there is
a large number of RT molecules in a virion; a relatively large number
of RT molecules may be required to complete viral DNA synthesis.
We performed phenotypic mixing experiments in which the virions
contained different amounts of catalytically active and catalytically inactive RTs to determine whether there is an excess of either polymerase or RNase H activity in the virion. The D110E mutation was
used to inactivate the polymerase; in parallel experiments, RNase H was
inactivated using either the D443A or E478Q mutation. The ability of
viruses containing different mixtures of active and inactive RTs to
replicate was determined. In HIV-1 virions, there is a modest excess of
polymerase activity; there is a greater excess of RNase H activity. The
process of reverse transcription in vivo was monitored by real-time
PCR. The analysis suggests that some RNase H mutations can interfere
with polymerase activity in vivo.
 |
MATERIALS AND METHODS |
Vector construction.
pNLNgoMIVR
E
.HSA was derived from
pNL4-3HSAR
E
(obtained from the AIDS Reagent
Program). A vector containing a unique SmaI site and a
unique Asp718 site in the pol coding region of
the pNL4-3-based vector was constructed. The Asp718 site at
position 6343 was removed by digesting
pNL4-3HSAR
E
with SalI and
BamHI. Then the restriction fragment containing the
Asp718 site at position 6343 was ligated into the cloning vector pKS
Asp718 (which was created by digesting pKS+ [obtained from Stratagene] with Asp718 and then using T4 DNA
polymerase and deoxynucleoside triphosphates [dNTPs] to fill in the
overhang and religating the vector). pKS containing the
SalI-to-BamHI fragment of
pNL4-3HSAR
E
was digested with
Asp718, then T4 DNA polymerase and dNTPs were used to fill
in the overhangs, and the vector was ligated using T4 DNA ligase. The
pKS cloning vector containing the SalI-to-BamHI fragment of pNL4-3HSAR
E
that lacked the
Asp718 site was digested with SalI and
BamHI, and the fragment containing the pNL-derived sequence
missing the Asp718 site was cloned into
pNL4-3HSAR
E
digested with SalI
and BamHI, generating the vector pNL4-3
Asp718#3. This
vector retains three of the Asp718 sites originally present in pNL4-3, but the site at position 6343 is destroyed. The
Asp718 site at position 9006 was removed by digesting
pNL4-3HSAR
E
with NsiI (removing
bases 1247 to 6738) and religating the vector. This vector, called
pNL-NsiI, was digested with Asp718, then treated with T4 DNA
polymerase and dNTPs to fill in the overhangs, and religated,
generating the vector pNL-NsiI
Asp718#4. pNL-NsiI
Asp718#4 was
digested with BamHI and NcoI. The fragment
containing the filled-in Asp718 site (position 9006) was
ligated to pNL pNL4-3
Asp718#3 digested with BamHI and
NcoI. This generated the vector pNL
Asp718#3,4. A unique
SmaI site was introduced into the pol coding
region at the 14th amino acid of RT. A PCR primer 5' of the
ApaI site at position 2005 and a PCR primer that generates
the SmaI site in RT were used to amplify
pNL4-3HSAR
E
. The PCR product was digested
with ApaI and SmaI, and the fragment was cloned
into PKS+
Asp718 digested with ApaI and SmaI.
Next, the Asp718 site at position 4154 was changed to an
NgoMIV site by using a PCR primer that anneals to the 5' end
of the RT coding region, a downstream PCR primer that changes the
Asp718 site at 4154 to an NgoMIV site, and a
previously described RT expression plasmid as the PCR template
(3). pNL4-3HSAR
E
was used as a
PCR template with a primer that changes the Asp718 site at
4154 to an NgoMIV site plus a primer that lies downstream of
the SalI site. These fragments were cloned as a
SmaI-to-NgoMIV fragment and an
NgoMIV-to-SalI fragment into pKS containing the ApaI-to-SmaI fragment as a three-way ligation.
Next, the ApaI-to-SalI fragments were moved into
pNL
3,4 digested with ApaI and SalI, creating
the final vector, pNLNgoMIVR
E
.HSA.
The plasmid encoding the vector with the D110E mutation in RT that
inactivates polymerase was created by digesting a previously described
RT expression plasmid containing the D110E mutation (3)
with SmaI and Asp718, gel eluting the 1.3-kb
fragment, and ligating the fragment into
pNLNgoMIVR
E
.HSA digested with
SmaI and Asp718 by using standard cloning procedures.
The E478Q and D443A mutations in RT were created by subcloning the
Asp718-to-
SalI fragment of
pNLNgoMIVR

E

.HSA into pKS+ and using a
QuickChange site-directed mutagenesis
kit (Stratagene) to introduce the
desired mutations into the RNase
H coding region. DNA sequence analysis
was performed to ensure
that the clones contained only the desired
mutation, and then
the mutated sequences were cloned into
pNLNgoMIVR

E

.HSA as an
Asp718-to-
SalI
fragment.
Cells, transfection, and infection.
The human embryonal
kidney cell line 293 was obtained from American Type Culture
Collection. The human osteosarcoma cell line HOS was obtained from
Richard Schwartz (Michigan State University, Lansing). 293 and HOS
cells were maintained in Dulbecco's modified Eagle's medium (Life
Technologies) supplemented with 5% fetal bovine serum, 5% newborn
calf serum, and penicillin (50 U/ml) plus streptomycin (50 µg/ml)
(Quality Biological).
Transfection, infection, and phenotyping protocol.
293 cells
were transfected with 2 µg of
pNLNgoMIVR
E
.HSA and 2 µg of pHCMV-g
(obtained from Jane Burns, University of California, San Diego) by the
calcium phosphate method. 293 cells were plated in 100-mm-diameter
dishes at a density of 1.8 × 106 cells per plate on
the day prior to transfection such that they would be approximately
30% confluent on the day of transfection The precipitate was added to
293 cells dropwise. Eight hours after transfection, the cells were
washed once with 8 ml of Dulbecco's phosphate-buffered saline (PBS;
Gibco BRL/Life Technologies), and fresh medium was added. The medium
was changed again 24 h after transfection. The 48-h supernatants were
harvested, clarified by low-speed centrifugation, filtered through a
Millex-GS 0.22-µm-pore-size filter (Millipore), and used to infected
HOS cells. The amount of p24 in the samples was determined using an
HIV-1 p24 antigen capture assay kit to control for the amounts of virus
in the samples (AIDS Vaccine Program, SAIC, Frederick, Md.). The virus
was allowed to adsorb to the cells for 6 h, and then fresh medium
was added. Forty-eight hours after infection, the cells were harvested
from the plate by treating with 1.5 ml of EDTA (Gibco BRL/Life
Technologies), an additional 2.5 ml of PBS was added; then the cells
were collected by centrifugation, washed, resuspended in 200 µl of
PBS, labeled with phycoerythrin-conjugated rat anti-mouse CD24
monoclonal antibody (PharMingen) by using standard procedures, fixed
with glutaraldehyde, and subjected to fluorescence-activated cell
sorting (FACS) to determine virus titer.
Transfections, infections, and nucleic acid extraction for
analysis of DNA synthesis using real-time PCR.
293 cells were
transfected with 5 µg of
pNLNgoMIVR
E
.HSA and 3 µg of pHCMV-g by
the calcium phosphate method. The transfections for the real-time PCR
experiments were performed with 5 µg of plasmid to maximize the
amount of virus in the supernatant and obtain acceptable levels of
residual plasmid carryover. After 7 h, the cells were rinsed two
times with 8 ml of PBS, and fresh medium was added. The plates were
inspected for the presence of precipitate by using a light microscope.
Twenty hours after transfection, the cells were washed with 8 ml of
PBS, and fresh medium was added. Thirty hours after transfection, the
medium was changed again. Forty-eight hours after transfection, the
plates were inspected with a light microscope to ensure that the
precipitate had been removed. Virus-containing supernatants were
harvested and clarified by centrifugation, and 5 ml of the
virus-containing supernatant was filtered through a 0.22-µm-pore-size
filter; 4 ml of virus was used to infect HOS cells, plated the day
prior to infection at 5 × 105 cells per
60-mm-diameter plate. The virus was allowed to adsorb to the cells for
4 h, the cells were washed three times with 4 ml of PBS, and fresh
medium was added. Twenty hours after infection, the total DNA was
isolated from the cells by the Blood DNA kit protocol (Qiagen) and
eluted with 200 µl of elution buffer.
Determination of DNA copy number by real-time PCR.
Real-time
PCR can be used to measure the amount of a specific nucleic acid
present in a solution. The technique has been described in the
literature (23, 35, 36); only a brief description is given
here. Real-time PCR monitors the amplification of a specific PCR
product during each amplification cycle. Taqman technology uses a
nucleic acid probe that contains a fluorescent group and a quencher.
This probe is degraded by the exonucleolytic activity of Taq
polymerase if it is part of a DNA duplex; degradation separates the
fluorescent group from the quencher, increasing the fluorescence in the
PCR sample. The fluorescence is monitored during each PCR cycle. When
the amount of fluorescence in the sample reaches a certain assigned
level, the PCR cycle number needed to achieve this threshold is
recorded. By comparing the threshold cycle in a sample to those of
standards containing known amounts of the target sequence, the number
of copies of the sequence in the sample is determined. Real-time PCR
was performed with an ABI7700 apparatus (Applied Biosystems) in a final
volume of 50 µl. The PCR mix contained 2× Universal PCR Master Mix
(Applied Biosystems) (25 µl), 10 µl of nucleic acid sample, and 5 µl of primers, probe, and water. The PCR primers and Taqman probes
were present at a final concentration of 200 nM. The unknown samples
were compared to duplicate samples containing 107 to
102 copies of plasmid DNA. The cycling conditions were 2 min at 50°C and 10 min at 95°C, then 40 cycles of 95°C for
15 s and 60°C for 1 min. The Taqman primer sets used to
monitor different stages of reverse transcription are given in
Table 1.
The HIV-1 2-LTR circle junction was cloned into the pKS plasmid as an
Asp718-to-
Sal fragment by PCR amplification from
the
2-LTR circles, using total DNA extracted from infected HOS cells
as
the template for the reaction. Serial dilutions of this plasmid
were
used as a standard to determine the copy number of 2-LTR
circles in the
samples as described for the determination of other
DNA copy numbers.
The Taqman set used to monitor the presence
of 2-LTR circles in the
samples is given in Table
1.
 |
RESULTS |
Vectors and replication assay.
The
pNLNgoMIVR
E
.HSA vectors (Fig.
1A) are based on previously described
vectors derived from the NL4-3 isolate of HIV-1 (7, 22).
In the experiments described here, the portion of RT located between
amino acids 14 and 427 of RT was derived from the BH10 isolate of
HIV-1. The env and vpr genes and are inactivated
in the vectors (7, 22); this limits the vectors to a
single cycle of replication. Cotransfecting 293 cells (Fig. 1B) with vector DNA and the plasmid, pHCMV-g, that expresses the vesicular stomatitis virus G envelope glycoprotein produced infectious virions (1, 69). Forty-eight-hour supernatants were harvested and used to infect HOS cells. The murine heat-stable antigen gene (hsa) (64) is expressed from the nef
reading frame of the vector. Infected cells were identified and
enumerated by being labeled with anti-HSA and subjected to FACS. Viral
titers were determined 48 h after infection.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 1.
HIV-1 based vector and biological assay for viral
infectivity. (A) The HIV-1 vector
pNLNgoMIVR E .HSA was created from the vector
pNL4-3HSAR E (obtained from the AIDS Reagent
Program) by introducing a unique SmaI restriction enzyme
site and making the Asp718 restriction enzyme site in the
pol coding region unique (see Materials and Methods for
details). The sequences encoding RT from the SmaI site to
the Asp718 site were derived from the BH10 isolate of HIV
and were subcloned from previously described HIV-1 RT expression
plasmids (3, 4). All other viral sequences in the vector
are derived from the NL4-3 strain of HIV-1. The vector expresses the
murine cell surface marker CD24 (HSA) from the nef open
reading frame. The env gene and the vpr gene have
been inactivated in this vector. The drawing is not to scale.
Infectious virus was produced by pseudotyping with the vesicular
stomatitis virus G envelope glycoprotein (expressed from pHCMV-g). The
vector undergoes only a single cycle of replication. pbs, primer
binding site. (B) 293 cells were cotransfected with
pNLNgoMIVR E .HSA vectors and pHCMV-g to
generate virus stocks. Forty-eight hours after transfection,
virus-containing supernatants were used to infect the HOS cell line.
Forty-eight hours following infection, the HOS cells were labeled with
antibody against the HSA. The cells were then fixed with formaldehyde
and subjected to FACS to determine the virus titer. ELISA,
enzyme-linked immunosorbent assay.
|
|
Phenotypic mixing experiments.
To determine if there is an
excess of polymerase or RNase H activity in HIV-1 virions, we performed
phenotypic mixing experiments in which virions were produced that
contain different amounts of catalytically active and inactive RT. 293 cells were cotransfected with different proportions of plasmids
encoding the wild-type vector
(pNLNgoMIVR
E
.HSA) and vectors that
contained mutations that inactivate polymerase (D110E) or RNase H
(D443A or E478Q). The relative amount of active RT was inferred from
the mixture of plasmids used to generate the virus.
293 cells were cotransfected with mixtures of plasmids encoding vectors
containing wild-type RT and the D110E mutation to
produce virions
containing 100% or approximately 50, 25, 10, or
0% of the polymerase
activity present in wild-type virions. The
effect of decreasing the
percentage of RT having polymerase activity
on relative virus titer is
shown in the Fig.
2A.
When 50% of the
plasmids encoded
wild-type RT and the other 50% encoded the D110E
mutant, the relative
infectivity of the virus stock was 42%. When
the percentage of
plasmids encoding wild-type RT was decreased
to 25%, the relative
infectivity was only 3% of the wild-type
level. When less than 25% of
the plasmid encoded wild-type RT,
there was no measurable infection of
HOS cells.

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 2.
Limiting polymerase or RNase H activity affects virus
infectivity. (A) 293 cells were cotransfected with different
proportions of plasmid containing vector wild-type RT and vector
containing the D110E mutation in RT. This generated virions containing
different percentages of active polymerase. (B) 293 cells were
cotransfected with different proportions of plasmid containing vector
encoding wild-type RT and vector containing the E478Q mutation in RT.
This generated virions containing different percentages of active RNase
H. (C) 293 cells were cotransfected with different proportions of
plasmid containing vector encoding wild-type RT and vector containing
the D443A mutation in RT. This generated virions containing different
percentages of active RNase H. In each case, the predicted percentage
of polymerase or RNase H activity is shown on the x axis,
and the relative infectivity, expressed as the percentage of the
wild-type control, is shown on the y axis. The relative
amounts of polymerase or RNase H activity are inferred from the
mixtures of plasmids used to generate the virions.
|
|
To measure the amount of excess RNase H activity in virions, we
prepared phenotypically mixed virions that contained 100,
50, 25, 10, and 0% of the RNase H activity of wild-type virions.
These virions
were prepared by cotransfecting 293 cells with plasmid
encoding the
wild-type vector and a vector encoding the E478Q
mutation in RT. The
effect of decreasing the amount of RNase H
activity on virus
replication was not as dramatic as the effect
of decreasing the
polymerase activity (Fig.
2B). When virions
contained 50 or 25% of the
wild-type level of RNase H, the specific
infectivity was 70 or 42%,
respectively, of that of the wild-type
vector. When the amount of RNase
H activity was decreased to 10%,
a greater effect was seen; the
relative infectivity was still
8% of the wild-type level. When all RT
in the virions had the
E478Q mutation, there was no measurable
infection.
When the D443A mutation was used to inactivate the RNase H activity,
the results were similar to the results of the E478Q
mixing
experiments, although the virions seemed to tolerate low
levels of the
D443A mutation better than low levels of the E478Q
mutation. When 50%
of the RT contained the D443A mutation there
was no measurable effect
on infectivity. When the percentage of
RT containing the D443A mutation
was increased to 75 or 90% the
relative infectivity was about 45 or
35%, respectively, of the
wild-type level. When the virion contained
only RT carrying the
D443A mutation, no infected HOS cells were
found.
Monitoring reverse transcription in vivo using real-time PCR.
Real-time PCR can be used to determine the copy number of specific
nucleic acids. The strategy used to monitor specific steps of reverse
transcription is shown in Fig. 3. As
shown in Fig. 3A, minus-strand DNA synthesis is initiated from a tRNA
primer bound to the RNA genome at the primer binding site. When the U5 and R regions of the viral RNA are copied into DNA, the resulting product is called minus-strand strong-stop DNA (
sssDNA). The synthesis of
sssDNA can be measured using a set of PCR primers and a
Taqman probe that anneals to the R and U5 regions of the DNA (Table 1).
Once
sssDNA is synthesized, it is transferred to the 3' end of the
RNA in a process called first strand (or minus-strand) transfer. Since
the U3 region of the RNA is copied into DNA immediately after the
strand transfer step, measuring viral DNA specific for U3 and comparing
it to the amount of
sssDNA monitors first-strand transfer. RT then
copies the viral structural genes; comparison of the amounts of DNA
specific for structural genes such as env, pol, and
gag can be used to monitor the progress of minus-strand
synthesis. Plus-strand DNA transfer can be measured if the PCR amplicon
spans the primer binding site. Plus-strand elongation and completion of
reverse transcription cannot be monitored directly because PCR-based
methods do not readily distinguish complementary DNA sequences.
However, monitoring the formation of the 2-LTR circles, which arise
from the ligation of the ends of the full-length linear viral DNA, can
be used as a surrogate for the completion of reverse
transcription. Viral DNA and locations of the Taqman primer sets used
to monitor individual steps in reverse transcription are depicted
in the Fig. 3B.

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 3.
Use of real-time PCR to monitor viral DNA synthesis. (A)
The process of reverse transcription. The thin line represents viral
RNA, and the thick line represents viral DNA synthesized by RT. RNase H
cleavage of RNA is shown by a dashed line. Measuring the amount of RU5
DNA synthesized monitors minus-strand DNA synthesis; measuring the
amount of U3 DNA synthesized monitors minus-strand DNA transfer;
measuring DNA synthesis in the gag gene monitors
minus-strand elongation. PCR primers spanning the primer binding site
(pbs) determine the amount of plus-strand transfer. Monitoring the
formation of 2-LTR circles using primers spanning the 2-LTR circle
junctions serves as a surrogate for the completion of reverse
transcription. The drawing is not to scale. (B) Structures of a DNA
provirus and of PCR primer and probe sets. Boxes on the viral DNA
indicate the positions of Taqman probe and primer sets during each
successive step of reverse transcription.
|
|
Limiting polymerase activity affects DNA synthesis.
Phenotypically mixed virions were generated by cotransfecting 293 cells
with different proportions of plasmids carrying a vector encoding
wild-type RT and vector encoding the D110E mutation in RT. The 48-h
supernatants were harvested, clarified by centrifugation, filtered, and
used to infect HOS cells for 4 h (see Materials and Methods for
details). The HOS cells were washed three times with 4 ml of PBS and
then maintained in medium for 20 h. Total DNA was extracted from
the infected cells, and the synthesis of viral DNA was analyzed by
real-time PCR.
In samples of virus that contain only RT carrying the D110E mutation,
2-LTR circles were not detected, and 1.0 × 10
2 copies
of RU5 and U3 were detected. We also detected 2.1 × 10
2 copies of
gag and 8.0 × 10
1 copies of strand transfer products, which we believe
represents
residual plasmid carried over from the transfection. Samples
derived
entirely from wild-type vector contained 2.4 × 10
6 copies of DNA corresponding to the RU5 region of HIV-1
(Table
2). Since 4 orders of magnitude
more products were detected in
cells infected with vectors carrying
wild-type RT, this small
amount of plasmid carryover is not critical to
the experiments.
There were 7.9 × 10
5 copies of U3,
indicating that about 30% of the

sssDNA undergoes
minus-strand DNA
transfer; the detection of 6.9 × 10
5 copies of
gag indicated that minus-strand DNA synthesis was also
quite
efficient. The presence of 2.0 × 10
5 copies of the
product spanning the primer binding site indicated
that plus-strand
transfer occurred approximately 10% of the time

sssDNA was made.
There was approximately 0.2% the amount of the
2-LTR circles as for
RU5 (5.5 × 10
3 versus 2.4 × 10
6).
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Quantitative analysis of viral DNA synthesis in cells
infected with phenotypically mixed viruses containing wild-type RT
and RT lacking polymerase activity
|
|
When the amount of RT containing polymerase activity was decreased, the
profile of DNA synthesis changed. There were significant
decreases in
the synthesis of

sssDNA in samples containing 20
and 10% polymerase
compared to the wild type (2.9 × 10
4 and 1.3 × 10
4 copies versus 2.4 × 10
6 copies).
Minus-strand DNA transfer and synthesis through the
gag gene
were relatively efficient in the samples containing 10
and 20% active
RT. However, the percentage of DNA undergoing plus-strand
DNA transfer
decreased relative to virions containing only wild-type
RT; no 2-LTR
circles were detected. These results are consistent
with the results of
the biological assay that indicated that retroviral
replication is
severely impaired when the percentage of polymerase
activity is less
than 25% of the wild-type level. These results
do not support the
suggestion that the low processivity of HIV-1
RT plays a role in the
requirement for a large number of active
RTs in a virion but suggest
instead that it is the initiation
of minus-strand synthesis and some
step or steps in plus-strand
synthesis that are limiting (see
Discussion).
Effects of limiting RNase H levels on DNA synthesis.
When the
virions contained only RT carrying the E478Q mutation, 1.6 × 104 copies of
sssDNA were produced (Table
3). Approximately 2 × 102 copies of U3, gag, and strand transfer
products were detected. As has already been discussed, approximately
102 copies presumably represent residual plasmid DNA from
the transfection of the 293 cells. No 2-LTR circles were detected. This
result suggests that there is a defect in the initiation of viral DNA synthesis as well as a block to first-strand transfer.
View this table:
[in this window]
[in a new window]
|
TABLE 3.
Quantitative analysis of viral DNA synthesis in cells
infected with phenotypically mixed viruses containing wild-type RT
and RT lacking RNase H activity
|
|
When virions containing only 10 or 5% of the wild-type level of RNase
H activity were used to infect HOS cells, DNA synthesis
was moderately
affected. Initiation of reverse transcription was
reduced by
approximately 90% (4.5 × 10
5 and 1.1 × 10
5 copies, for 10 and 5% activity respectively, versus
2.4 × 10
6 for the wild type). About 30% of the

sssDNAs were able to complete
minus-strand transfer. DNA synthesis
through the structural genes
was relatively efficient for those samples
that completed strand
transfer. In samples with limiting RNase H
activity, plus-strand
DNA transfer occurred about 5% of the time

sssDNA was synthesized.
Circle junctions were detected at about
0.05% of the level of

sssDNA when 10 or 5% RNase H activity was
present.
Virions containing defective RTs carrying the D110E mutation to
inactivate polymerase and D443A or E478Q to inactivate RNase H infect
cells inefficiently.
To determine if virions containing the
polymerase and RNase H activities on separate RTs can undergo reverse
transcription and infect cells, we performed phenotypic mixing
experiments in which approximately half of the RTs in the virion
possess the D110E mutation and half possess either the E478Q or D443A
mutation. The resulting virions are solely dependent on the RTs
containing the D110E mutation for RNase H activity and on the RTs
containing either E478Q or D443A for polymerase activity.
293 cells were cotransfected with a mixture of plasmids encoding
wild-type RT or a 50-50 mixture of plasmids encoding the
D110E mutation
to inactivate the polymerase activity of RT and
plasmid encoding either
the E478Q or D443A mutation to inactivate
RNase H activity of RT.
Results for the viruses containing the
two RT activities on separate RT
molecules are shown in Fig.
4.
The
infection of HOS cells was reduced to approximately 5 or 8%,
respectively, for viruses containing the D443A-D110E mixture of
RTs or
the E478Q-D110E mixture of RTs compared to virions containing
wild-type
RT. This result indicates that the two defective RTs
complement
inefficiently. A similar result has been reported for
MLV
(
60).

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 4.
RTs with inactive polymerase and inactive RNase H
complement inefficiently. In control experiments, 293 cells were
transfected with plasmids containing vectors encoding wild-type RT or
the E478Q or D443A mutant. In parallel, cells were cotransfected with
equal proportions of plasmids carrying the D110E mutant and the E478Q
mutant or the D110E mutant and the D443A mutant. This generated virions
containing only wild-type RT, only the two RNase H mutations, or equal
mixtures of RTs defective in polymerase and RNase H. The RT composition
of the virions is shown on the x axis, and the relative
infectivity is shown on the y axis.
|
|
 |
DISCUSSION |
Phenotypically mixed HIV-1 vectors that undergo only a single
cycle of replication were used to measure the amount of excess polymerase and RNase H activity in virions. When the D11OE mutation was
used to reduce the amount of active RT in the virion 50%, infectivity
was 42% of the wild-type level. While this still allows a substantial
amount of viral replication, it would be expected to cause a reduction
in viral fitness, and we would expect viruses whose RTs had
approximately half the normal level of polymerase to be selected
against during passage relative to the wild-type virus. Replication was
severely impaired when less than 25% of the RT in the virions
contained active polymerase. When the D443A mutation was used to
inactivate RNase H by 90%, the virions retained 35% of their
infectivity. The analysis of mixed virions sets the stage for the
analysis of the replication of vectors encoding different RT mutants
whose biochemical properties have been previously characterized in
vitro. The characterization of reverse transcription in a
phenotypically mixed virion containing 25% wild-type RT and 75%
inactive RT establishes a baseline for the comparison of different RT
mutants that contain approximately 25% of a given RT activity (polymerase or RNase H) in in vitro assays.
The ability to monitor reverse transcription accurately by measuring
specific DNA intermediates allows us to determine where reverse
transcription fails for virions containing limiting amounts of
polymerase or RNase H activity. Determining where reverse transcription fails defines the limiting activity (or activities) for a mixed virion
or a particular RT mutant.
In the phenotypically mixed virions, a substantial decrease in virus
infectivity was observed when the virions contained 25% or less
catalytically active polymerase. Since the virions must package enough
polymerase activity to ensure that that viral RNA genome is completely
reverse transcribed, this result shows that multiple RTs are needed to
complete reverse transcription. It has been estimated that virions
contain approximately 50 copies of RT; this suggests more than 12 RTs
are needed to efficiently complete viral DNA synthesis. RT has a
relatively low affinity for its template-primer, and DNA polymerization
in vitro results in the synthesis of relatively short segments of DNA.
These properties of RT could contribute to the requirement for multiple
RTs to convert the RNA into double-stranded DNA. When the polymerase activity of RT mutants was measured in vitro, the lowest amount of
polymerase activity for a mutant RT (G190E) found in HIV-1-infected patients was about 20% the wild-type level [using poly(rC)-oligo(dG) as the substrate] (5). This is similar to the amount of
active polymerase in the phenotypically mixed virions that were still able to infect cells in this study. The G190E mutant also had reduced
processivity compared to wild-type RT (5). The fact that
this mutant displayed poor processivity and decreased polymerase activity but can be selected in HIV-1-infected individuals supports the
notion that there is excess polymerase activity in the virion and that
multiple RTs are involved in reverse transcription.
The dramatic reduction in the amount of
sssDNA synthesized when the
amount of active polymerase was systematically reduced in the virions
indicates a failure at the level of initiation. Although the virions
with limited polymerase activity still contained enough polymerase
activity to extend most of the minus-strand DNAs that were initiated,
there was little, if any, plus-strand transfer and no 2-LTR circles
were found, suggesting a problem with plus-strand DNA synthesis. Taken
together, these data suggest that when the amount of active RT is
limiting, the critical stages are the initiation of minus-strand DNA
synthesis and the synthesis of plus-strand DNA. Processivity, at least
in terms of the synthesis of minus-strand DNA, does not appear to be
limiting. This is a somewhat surprising result; it suggests that the
processivity of minus-strand DNA synthesis may be better in vivo than
in vitro. The failure at the plus-strand transfer step implies failure
at some step in plus-strand synthesis. Because the initiation of minus-strand DNA synthesis appears to be a limiting step in viral DNA
synthesis, it is tempting to speculate that the initiation of
plus-strand DNA synthesis is also a limiting step. However, PCR-based
technology does not readily distinguish between plus-strand and
minus-strand DNA, and we cannot, with the data now available, determine
what step in plus-strand DNA synthesis and/or plus-strand transfer is limiting.
The replication of phenotypically mixed virions containing reduced
amounts of RNase H activity indicated that there is a greater excess of RNase H activity in virions than there is of polymerase activity. Viruses containing relatively small amounts of the RT with
the D443A mutation replicated better than viruses containing the
equivalent amount of the RT with the E478Q mutation. Virions that
contain RT with the E478Q mutation are defective in the initiation of
viral DNA synthesis; it is possible that the effect of the E478Q
mutation on polymerization contributes to the replication defect. This
excess of RNase H activity in HIV-1 virions does not cause premature
degradation of the RNA template or result in premature cleavage of the
ppt. We would estimate, based on the data obtained with the D443A
mutant, as few as five RTs produce sufficient RNase H cleavage for
HIV-1 replication. In support of the estimate that there is
approximately a 10-fold excess of RNase H activity in HIV-1 virions,
HIV-2 RT has only about 10% the RNase H activity of HIV-1 RT when the
specific activities of the two enzymes are compared in vitro
(50). The fact that there is a large excess of RNase H
activity in HIV-1 virions suggests that the specificity of RNase H
cleavage is tightly controlled. Cleavage of the RNA by RNase H must be
precise in order to create the proper ends of the linear viral DNA that
serves as the substrate for integration into the host genome. We have
suggested that this specificity is based not on nucleic acid sequence
but on the structure of the nucleic acid in the context of the enzyme
(4, 17, 48). The polymerase domain has a substantial role
in binding the nucleic acid. The observation that mutations in the
polymerase domain of RT affect the specificity of cleavage of the RNA
template indicates that the proper positioning of nucleic acid within
RT is important for specific RNase H cleavage (4, 17, 42). It would appear that the control of cleavage specificity is sufficient to allow the virion to contain a considerable excess of RNase H activity.
Virions that contained significantly reduced levels of RNase H activity
were deficient in minus-strand transfer. This observation is expected
based on the requirement for RNase H cleavage for the minus-strand
transfer reaction (16, 56, 59). However, we also found
that virions containing the E478Q mutation did not efficiently
synthesize
sssDNA. The D443N mutation was reported to have minimal
effects on polymerase activity when homopolymeric templates were used
as substrates (39); however, when heteropolymeric templates were used, this RNase H mutant appeared to interfere with DNA
synthesis (12, 40). There are MLV RNase H mutants that
have similar properties (2, 20, 57, 60). The E478Q mutation has been reported to interfere with DNA synthesis in vitro;
however, initiation was not affected (26). If the RNase H
mutations caused a reduction in processivity in vivo, we would have
seen greater effects on the synthesis of minus-strand DNA. Severely
limiting the RNase H activity appears to have a minimal effect on the
late stages of viral DNA synthesis. The ratio of the gag DNA
to the plus-strand transfer product and the ratio of the circle
junction to either the gag DNA or the plus-strand transfer
product are approximately the same in the virions that contain 100%
wild-type RT and those that contain 5% wild-type RT, despite the fact
that infectivity is reduced. The two steps that appear to be most
affected are
sssDNA synthesis and first-strand transfer.
There are two things that are surprising about the results. First, it
seems unlikely that the RNase H mutations are affecting general DNA
synthesis (processivity); the deficient virions extend minus-strand DNA
from U3 through gag reasonably efficiently. The problem
seems to be specific for initiation of DNA synthesis, a step that
appears to be limiting when the polymerase activity is reduced. This
suggests that the initiation of minus-strand DNA synthesis is quite
difficult in vivo and is sensitive to alterations in the levels of both
polymerase and RNase H activity. Second, it appears that the
first-strand transfer reaction is more sensitive to limiting RNase H
activity than is the generation or removal of the plus-strand (ppt)
primer. The data also suggest that removal of the tRNA primer is not
limiting in vivo. Although it might seem at first that the steps of
viral DNA synthesis at which RNase H must act with considerable
precision (generation and removal of the plus-strand primer and removal
of the minus-strand primers) would be the steps that would be most
sensitive if the level of RNase H was limiting, this does not appear to
be the case. One possible explanation is that the minus-strand transfer
step, which is sensitive to limiting the level of RNase H activity, is
actually a carefully regulated process. Because the end of the HIV-1
genome is a hairpin (transactivation response region),
sssDNA hairpin formation can be seen in vitro; hairpin formation does not appear to
occur in vivo. The available data suggest that RNase H cleavage is
carefully controlled. In the presence of nucleocapsid, a specific RNA
segment from the 5' end of the genome blocks hairpin formation and
promotes strand transfer (11, 14). It would appear that the requirements are equally specific in vivo, which would explain why
strand transfer is sensitive to limiting amounts of RNase H activity.
 |
ACKNOWLEDGMENTS |
pNL4-3HSAR
E
from Nathaniel Landau,
was obtained through the AIDS Research and Reference Reagent Program,
Division of AIDS, NIAID, NIH.
We thank Marilyn Powers for DNA sequencing, Louise Finch for FACS
analysis, and Hilda Marusiodis for help in preparing the manuscript.
Research in Stephen H. Hughes' laboratory was supported by the
National Cancer Institute and by the National Institute for General
Medical Sciences.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: HIV Drug
Resistance Program, NCI-Frederick, P.O. Box B, Building 539, Room 130A,
Frederick, MD 21702-1201. Phone: (301) 846-1619. Fax: (301) 846-6966. E-mail: Hughes{at}ncifcrf.gov.
 |
REFERENCES |
| 1.
|
Bartz, S. R., and M. A. Vodicka.
1997.
Production of high-titer human immunodeficiency virus type 1 pseudotyped with vesicular stomatitis virus glycoprotein.
Methods
12:337-342[CrossRef][Medline].
|
| 2.
|
Blain, S. W., and S. P. Goff.
1995.
Effects on DNA synthesis and translocation caused by mutations in the RNase H domain of Moloney murine leukemia virus reverse transcriptase.
J. Virol.
69:4440-4452[Abstract].
|
| 3.
|
Boyer, P. L.,
A. L. Ferris, and S. H. Hughes.
1992.
Cassette mutagenesis of the reverse transcriptase of human immunodeficiency virus type 1.
J. Virol.
66:1031-1039[Abstract/Free Full Text].
|
| 4.
|
Boyer, P. L.,
A. L. Ferris, and S. H. Hughes.
1992.
Mutational analysis of the fingers domain of human immunodeficiency virus type 1 reverse transcriptase.
J. Virol.
66:7533-7537[Abstract/Free Full Text].
|
| 5.
|
Boyer, P. L.,
H.-Q. Gao, and S. H. Hughes.
1998.
A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template primer.
Antimicrob. Agents Chemother.
42:447-452[Abstract/Free Full Text].
|
| 6.
|
Coffin, J. M.,
S. H. Hughes, and H. E. Varmus (ed.).
1997.
Retroviruses.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 7.
|
Connor, R. I.,
B. K. Chen,
S. Choe, and N. R. Landau.
1995.
Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes.
Virology
206:935-944[CrossRef][Medline].
|
| 8.
|
Davies, J. F., II,
Z. Hostomska,
Z. Hostomsky,
S. R. Jordan, and D. A. Matthews.
1991.
Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase.
Science
252:88-95[Abstract/Free Full Text].
|
| 9.
|
DeStefano, J. J.,
R. G. Buiser,
L. M. Mallaber,
T. W. Myers,
R. A. Bambara, and P. J. Fay.
1991.
Polymerization and RNase H activities of the reverse transcriptases from avian myeloblastosis, human immunodeficiency and Moloney murine leukemia viruses are functionally uncoupled.
J. Biol. Chem.
266:7423-7431[Abstract/Free Full Text].
|
| 10.
|
Di Marzo Veronese, F.,
T. D. Copeland,
A. L. DeVico,
R. Rahman,
S. Oroszlan,
R. C. Gallo, and M. G. Sarngadharan.
1986.
Characterization of highly immunogenic p66/p55 as the reverse transcriptase of HTL VIII/LAV.
Science
231:1289-1291[Abstract/Free Full Text].
|
| 11.
|
Driscoll, M. D.,
M.-P. Golinelli, and S. H. Hughes.
2001.
In vitro analysis of human immunodeficiency virus type 1 minus-strand strong-stop DNA synthesis and genomic RNA processing.
J. Virol.
75:672-686[Abstract/Free Full Text].
|
| 12.
|
Dudding, L. R.,
N. C. Nkabinde, and V. Mizrahi.
1991.
Analysis of the RNA- and DNA-dependent DNA polymerase activities of point mutants of HIV-1 reverse transcriptase lacking ribonuclease H activity.
Biochemistry
30:10498-10506[CrossRef][Medline].
|
| 13.
|
Dudding, L. R., and V. Mizrahi.
1993.
Rapid kinetic analysis of a point mutant of HIV-1 reverse transcriptase lacking ribonuclease H activity.
Biochemistry
32:6116-6120[CrossRef][Medline].
|
| 14.
|
Fu, T. B., and J. Taylor.
1992.
When retroviral reverse transcriptases reach the ends of their RNA templates.
J. Virol.
66:4271-4278[Abstract/Free Full Text].
|
| 15.
|
Furfine, E. S., and J. E. Reardon.
1991.
Human immunodeficiency virus reverse transcriptase ribonuclease H: specificity of tRNA(Lys3)-primer excision.
Biochemistry
30:7041-7046[CrossRef][Medline].
|
| 16.
|
Furfine, E. S., and J. E. Reardon.
1991.
Reverse-transcriptase-RNaseH from human immunodeficiency virus: relationship of the DNA polymerase and RNA hydrolysis activities.
J. Biol. Chem.
266:406-412[Abstract/Free Full Text].
|
| 17.
|
Gao, H.-Q.,
P. L. Boyer,
E. Arnold, and S. H. Hughes.
1998.
Effects of mutations in the polymerase domain on the polymerase, RNase H and strand transfer activities of human immunodeficiency virus type 1 reverse transcriptase.
J. Mol. Biol.
277:559-572[CrossRef][Medline].
|
| 18.
|
Gilboa, E.,
S. W. Mitra,
S. Goff, and D. Baltimore.
1979.
A detailed model of reverse transcription and tests of crucial aspects.
Cell
18:93-100[CrossRef][Medline].
|
| 19.
|
Gopalakrishnan, V.,
J. A. Peliska, and S. J. Benkovic.
1992.
Human immunodeficiency virus type 1 reverse transcriptase: spatial and temporal relationship between the polymerase and RNase H activities.
Proc. Natl. Acad. Sci. USA
89:10763-10767[Abstract/Free Full Text].
|
| 20.
|
Guo, J.,
W. Wu,
Z. Y. Yuan,
K. Post,
R. J. Crouch, and J. G. Levin.
1995.
Defects in primer-template binding, processive DNA synthesis, and RNase H activity associated with the chimeric reverse transcriptases having the murine leukemia virus polymerase domain joined to Escherichia coli RNase H.
Biochemistry
34:5018-5029[CrossRef][Medline].
|
| 21.
|
Hayman, M. J.
1978.
Viral polyproteins in chick embryo fibroblasts infected with avian sarcoma leukosis viruses.
Virology
85:241-252[CrossRef][Medline].
|
| 22.
|
He, J.,
S. Choe,
R. Walker,
P. Di Marzio,
D. O. Morgan, and N. R. Landau.
1995.
Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity.
J. Virol.
69:6705-6711[Abstract].
|
| 23.
|
Heid, C. A.,
J. Stevens,
K. J. Livak, and P. M. Williams.
1996.
Real time quantitative PCR.
Genome Res.
6:986-994[Abstract/Free Full Text].
|
| 24.
|
Hostomsky, Z.,
Z. Homstomska,
G. O. Hudson,
E. W. Moomaw, and B. R. Nodes.
1991.
Reconstitution in vitro of RNase H activity by using purified N-terminal and C-terminal domains of HIV-1 reverse transcriptase.
Proc. Natl. Acad. Sci. USA
88:1148-1152[Abstract/Free Full Text].
|
| 25.
|
Hughes, S. H.,
E. Arnold, and Z. Hostomsky.
1998.
RNase H of retroviral reverse transcriptases, p. 195-224.
. Chapter In R. J. Crouch and J. J. Toulmé (ed.), Ribonucleases H. Les Editions INSERM, Paris, France.
|
| 26.
|
Isel, C.,
J.-M. Lanchy,
S. F. Le Grice,
C. Ehresmann,
B. Ehresmann, and R. Marquet.
1996.
Specific initiation and switch to elongation of human immunodeficiency virus type 1 reverse transcriptase require the post-transcriptional modifications of primer tRNA3lys.
EMBO J.
15:917-924[Medline].
|
| 27.
|
Jacobo-Molina, A.,
J. Ding,
R. G. Nanni,
A. D. Clark, Jr.,
X. Lu,
C. Tantillo,
R. L. Williams,
G. Kamer,
A. L. Ferris,
P. Clark,
A. Hizi,
S. H. Hughes, and E. Arnold.
1993.
Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA.
Proc. Natl. Acad. Sci. USA
90:6320-6324[Abstract/Free Full Text].
|
| 28.
|
Jamjoon, G. A.,
R. B. Naso, and R. B. Arlinghaus.
1977.
Further characterization of intracellular precursor polyproteins of Rauscher leukemia virus.
Virology
78:11-34[CrossRef][Medline].
|
| 29.
|
Katayanagi, K.,
M. Miyagawa,
M. Matsushima,
M. Ishikawa,
S. Kanaya,
M. Ikehara,
T. Mastsuzaki, and K. Morikawa.
1990.
Three-dimensional structure of ribonuclease H from E. coli.
Nature
347:306-309[CrossRef][Medline].
|
| 30.
|
Keck, J. L., and S. Marqusee.
1995.
Substitution of a highly basic helix/loop sequence into the RNase H domain of human immunodeficiency virus reverse transcriptase restores its Mn2+ dependent RNase H activity.
Proc. Natl. Acad. Sci. USA
92:2740-2744[Abstract/Free Full Text].
|
| 31.
|
Kohlstaedt, L. A.,
J. Wang,
J. M. Friedman,
P. A. Rice, and T. A. Steitz.
1992.
Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor.
Science
256:1783-1790[Abstract/Free Full Text].
|
| 32.
|
Kotewicz, M. L.,
C. M. Samson,
J. M. D' Alessio, and G. F. Gerard.
1988.
Isolation of cloned Moloney murine leukemia virus reverse transcriptase lacking ribonuclease H activity.
Nucleic Acids Res.
16:265-277[Abstract/Free Full Text].
|
| 33.
|
Le Grice, S. F. J.,
T. Naas,
B. Wohlgensinger, and O. Schatz.
1991.
Subunit selective mutagenesis indicates minimal polymerase activity in heterodimer-associated p51 HIV-1 reverse transcriptase.
EMBO J.
10:3905-3911[Medline].
|
| 34.
|
Levin, J. G.,
R. J. Crouch,
K. Post,
S. C. Hu,
D. McKelvin,
M. Zweig,
D. L. Court, and B. I. Gerwin.
1988.
Functional organization of the murine leukemia virus reverse transcriptase: characterization of a bacterially expressed AKR DNA polymerase deficient in RNase H activity.
J. Virol.
62:4376-4380[Abstract/Free Full Text].
|
| 35.
|
Lie, Y. S., and C. J. Petropoulos.
1998.
Advances in quantitative PCR technology; 5' nuclease assays.
Curr. Opin. Biotechnol.
9:43-48[CrossRef][Medline].
|
| 36.
|
Livak, K. J.,
S. J. A. Flood,
J. Marmaro,
W. Giusti, and K. Deetz.
1995.
Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization.
PCR Methods Appl.
4:357-362[Medline].
|
| 37.
|
Luo, G. X., and J. Taylor.
1990.
Template switching by reverse transcriptase during DNA synthesis.
J. Virol.
64:4321-4328[Abstract/Free Full Text].
|
| 38.
|
Mitra, S. W.,
S. Goff,
E. Gilboa, and D. Baltimore.
1979.
Synthesis of a 600-nucleotide-long plus-strand DNA by virions Moloney murine leukemia virus.
Proc. Natl. Acad. Sci. USA
76:4355-4359[Abstract/Free Full Text].
|
| 39.
|
Mizrahi, V.,
M. T. Usdin,
A. Harington, and L. R. Dudding.
1990.
Site-directed mutagenesis of the conserved Asp-443 and Asp-498 carboxy-terminal residues of HIV-1 reverse transcriptase.
Nucleic Acids Res.
18:5359-5363[Abstract/Free Full Text].
|
| 40.
|
Mizrahi, V.,
R. L. Brooksbanks, and N. C. Nkabinde.
1994.
Mutagenesis of the conserved aspartic acid 443, glutamic acid 478, aspargine 494, and aspartic acid 498 residues in the ribonuclease H domain of p66/p51 human immunodeficiency virus type I reverse transcriptase.
J. Biol. Chem.
269:19245-19249[Abstract/Free Full Text].
|
| 41.
|
Oppermann, H.,
J. M. Bishop,
H. E. Varmus, and L. Levintow.
1977.
A joint product of the genes gag and pol of avian sarcoma virus: a possible precursor of reverse transcriptase.
Cell
12:993-1005[CrossRef][Medline].
|
| 42.
|
Palaniappan, C.,
M. Wisniewski,
P. S. Jacques,
S. F. Le Grice,
P. J. Fay, and R. A. Bambara.
1997.
Mutations within the primer grip region of reverse transcriptase result in loss of RNase H function.
J. Biol. Chem.
272:11157-11164[Abstract/Free Full Text].
|
| 43.
|
Post, K.,
J. Guo,
E. Kalman,
T. Uchida,
R. J. Crouch, and J. G. Levin.
1993.
A large deletion in the connection subdomain of murine leukemia virus reverse transcriptase or replacement of the RNase H domain with Escherichia coli RNase H results in altered polymerase and RNase H activities.
Biochemistry
32:5508-5517[CrossRef][Medline].
|
| 44.
|
Pullen, K. A., and J. J. Champoux.
1990.
Plus-strand origin for human immunodeficiency virus type 1: implications for integration.
J. Virol.
64:6274-6277[Abstract/Free Full Text].
|
| 45.
|
Pullen, K. A.,
L. K. Ishimoto, and J. J. Champoux.
1992.
Incomplete removal of the RNA primer for minus-strand DNA synthesis by human immunodeficiency virus type 1 reverse transcriptase.
J. Virol.
66:367-373[Abstract/Free Full Text].
|
| 46.
|
Rattray, A. J., and J. J. Champoux.
1989.
Plus-strand priming by Moloney murine leukemia virus. The sequence features important for cleavage by RNase H.
J. Mol. Biol.
208:445-456[CrossRef][Medline].
|
| 47.
|
Repaske, R.,
J. W. Hartley,
M. F. Kavlick,
R. R. O'Neill, and J. B. Austin.
1989.
Inhibition of RNase H activity and viral replication by single mutations in the 3' region of Moloney murine leukemia virus reverse transcriptase.
J. Virol.
63:1460-1464[Abstract/Free Full Text].
|
| 48.
|
Sarafianos, S. G.,
K. Das,
C. Tantillo,
A. D. Clark, Jr.,
J. Ding,
J. Whitcomb,
M. Gait,
P. L. Boyer,
S. H. Hughes, and E. Arnold.
2001.
Crystal structure of HIV-1 reverse transcriptase in complex with a polypurine tract RNA:DNA.
EMBO J.
20:1449-1461[CrossRef][Medline].
|
| 49.
|
Schatz, O.,
F. V. Cromme,
T. Naas,
D. Lindemann,
J. Mous, and S. F. J. Le Grice.
1990.
Inactivation of the RNase H domain of HIV-1 reverse transcriptase blocks viral infectivity, p. 293-404.
In
T. S. Papas (ed.), Gene regulation and AIDS. Portfolio, Houston, Tex.
|
| 50.
|
Shaharabany, M., and A. Hizi.
1992.
The catalytic functions of chimeric reverse transcriptases of human immunodeficiency viruses type 1 and type 2.
J. Biol. Chem.
267:3674-3678[Abstract/Free Full Text].
|
| 51.
|
Smith, J. K.,
A. Cywinski, and J. M. Taylor.
1984.
Specificity of initiation of plus-strand DNA by Rous sarcoma virus.
J. Virol.
52:314-319[Abstract/Free Full Text].
|
| 52.
|
Smith, J. S., and M. Roth.
1992.
Specificity of human immunodeficiency virus-1 reverse transcriptase-associated ribonuclease H in removal of the minus-strand primer, tRNA .
J. Biol. Chem.
267:15071-15079[Abstract/Free Full Text].
|
| 53.
|
Smith, J. S.,
K. Gritsman, and M. J. Roth.
1994.
Contributions of DNA polymerase subdomains to the RNase H activity of human immunodeficiency virus type 1 reverse transcriptase.
J. Virol.
68:5721-5729[Abstract/Free Full Text].
|
| 54.
|
Stahl, S. J.,
J. D. Kaufman,
S. Vikic-Topic,
R. J. Crouch, and P. T. Wingfield.
1994.
Construction of an enzymatically active ribonuclease H domain of human immunodeficiency virus type 1 reverse transcriptase.
Protein Eng.
7:1103-1108[Abstract/Free Full Text].
|
| 55.
|
Stromberg, K.,
N. E. Hurley,
N. L. Davis,
R. R. Rueckert, and E. Fleisnner.
1974.
Structural studies of avian myeloblastosis virus: Comparison of polypeptides in virion and core component by dodecyl sulfate-polyacrylamide gel electrophoresis.
J. Virol.
13:513-528[Abstract/Free Full Text].
|
| 56.
|
Tanese, N. T.,
A. Telesntitsky, and S. P. Goff.
1991.
Abortive reverse transcription by mutants of Moloney murine leukemia virus deficient in the reverse transcriptase-associated RNase H function.
J. Virol.
65:4387-4397[Abstract/Free Full Text].
|
| 57.
|
Tanese, N., and S. P. Goff.
1988.
Domain structure of the Moloney murine leukemia virus reverse transcriptase: mutational analysis and separate expression of the polymerase and RNase H activities.
Proc. Natl. Acad. Sci. USA
85:1777-1781[Abstract/Free Full Text].
|
| 58.
|
Taylor, J. M., and T. W. Hsu.
1980.
Reverse transcription of avian sarcoma virus RNA into DNA might involve copying of the tRNA primer.
J. Virol.
33:531-534[Abstract/Free Full Text].
|
| 59.
|
Telesnitsky, A.,
S. W. Blain, and S. P. Goff.
1992.
Defects in Moloney murine leukemia virus replication caused by a reverse transcriptase mutation modeled on the structure of Escherichia coli ribonuclease H.
J. Virol.
66:615-622[Abstract/Free Full Text].
|
| 60.
|
Telesnitsky, A., and S. P. Goff.
1993.
Two defective forms of reverse transcriptase can complement to restore retroviral infectivity.
EMBO J.
12:4433-4438[Medline].
|
| 61.
|
Tisdale, M.,
T. Schultze,
B. A. Larder, and K. Moelling.
1991.
Mutations within the RNase H domain of HIV-1 reverse transcriptase abolish viral infectivity.
J. Gen. Virol.
72:59-66[Abstract/Free Full Text].
|
| 62.
|
Varmus, H. E.,
S. Heasley,
H.-J. Kung,
H. Opperman,
V. C. Smith,
J. M. Bishop, and P. R. Shank.
1978.
Kinetics, of synthesis, structure, and purification of avian sarcoma virus-specific DNA made in the cytoplasm of acutely infected cells.
J. Mol. Biol.
120:55-82[CrossRef][Medline].
|
| 63.
|
Volkmann, S.,
B. M. Wöhrl,
M. Tisdale, and K. Moelling.
1993.
Enzymatic analysis of two HIV-1 reverse transcriptase mutants with mutations in the carboxyl-terminal amino acid residues conserved among retroviral ribonucleases H.
J. Biol. Chem.
268:2674-2683[Abstract/Free Full Text].
|
| 64.
|
Wegner, R. H.,
J. M. Rochelle,
M. F. Seldin,
G. Kohler, and P. J. Nielsen.
1993.
The heat stable antigen (mouse CD24) gene is differentially regulated but has a housekeeping promoter.
J. Biol. Chem.
268:23345-23352[Abstract/Free Full Text].
|
| 65.
|
Whitcomb, J. M.,
R. Kumar, and S. H. Hughes.
1990.
Sequence of the circle junction of human immunodeficiency virus type 1: implications for reverse transcription and integration.
J. Virol.
64:4903-4906[Abstract/Free Full Text].
|
| 66.
|
Whitcomb, J. M., and S. H. Hughes.
1992.
Retroviral reverse transcription and integration: progress and problems.
Annu. Rev. Cell Biol.
8:275-306[CrossRef].
|
| 67.
|
Wohrl, B. M., and K. Moelling.
1990.
Interaction of HIV-1 ribonuclease H with polypurine tract containing RNA-DNA hybrids.
Biochemistry
29:10141-10147[CrossRef][Medline].
|
| 68.
|
Yang, W.,
W. A. Hendrickson,
R. J. Crouch, and Y. Satow.
1990.
Structure of ribonuclease H phased at 2 Å resolution by MAD analysis of the selenomethionyl protein.
Science
249:1398-1405[Abstract/Free Full Text].
|
| 69.
|
Yee, J. K.,
T. Friedmann, and J. C. Burns.
1994.
Generation of high-titer pseudotyped retroviral vectors with very broad host range.
Methods Cell Biol.
43:99-112.
|
Journal of Virology, July 2001, p. 6537-6546, Vol. 75, No. 14
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.14.6537-6546.2001
This article has been cited by other articles:
-
Dong, C., Kwas, C., Wu, L.
(2009). Transcriptional Restriction of Human Immunodeficiency Virus Type 1 Gene Expression in Undifferentiated Primary Monocytes. J. Virol.
83: 3518-3527
[Abstract]
[Full Text]
-
Thomas, J. A., Bosche, W. J., Shatzer, T. L., Johnson, D. G., Gorelick, R. J.
(2008). Mutations in Human Immunodeficiency Virus Type 1 Nucleocapsid Protein Zinc Fingers Cause Premature Reverse Transcription. J. Virol.
82: 9318-9328
[Abstract]
[Full Text]
-
Oh, J., McWilliams, M. J., Julias, J. G., Hughes, S. H.
(2008). Mutations in the U5 Region Adjacent to the Primer Binding Site Affect tRNA Cleavage by Human Immunodeficiency Virus Type 1 Reverse Transcriptase In Vivo. J. Virol.
82: 719-727
[Abstract]
[Full Text]
-
Dong, C., Janas, A. M., Wang, J.-H., Olson, W. J., Wu, L.
(2007). Characterization of Human Immunodeficiency Virus Type 1 Replication in Immature and Mature Dendritic Cells Reveals Dissociable cis- and trans-Infection. J. Virol.
81: 11352-11362
[Abstract]
[Full Text]
-
Sakuragi, J.-i., Sakuragi, S., Shioda, T.
(2007). Minimal Region Sufficient for Genome Dimerization in the Human Immunodeficiency Virus Type 1 Virion and Its Potential Roles in the Early Stages of Viral Replication. J. Virol.
81: 7985-7992
[Abstract]
[Full Text]
-
Mbisa, J. L., Barr, R., Thomas, J. A., Vandegraaff, N., Dorweiler, I. J., Svarovskaia, E. S., Brown, W. L., Mansky, L. M., Gorelick, R. J., Harris, R. S., Engelman, A., Pathak, V. K.
(2007). Human Immunodeficiency Virus Type 1 cDNAs Produced in the Presence of APOBEC3G Exhibit Defects in Plus-Strand DNA Transfer and Integration. J. Virol.
81: 7099-7110
[Abstract]
[Full Text]
-
Thomas, J. A., Ott, D. E., Gorelick, R. J.
(2007). Efficiency of Human Immunodeficiency Virus Type 1 Postentry Infection Processes: Evidence against Disproportionate Numbers of Defective Virions. J. Virol.
81: 4367-4370
[Abstract]
[Full Text]
-
Mandal, D., Dash, C., Le Grice, S. F. J., Prasad, V. R.
(2006). Analysis of HIV-1 replication block due to substitutions at F61 residue of reverse transcriptase reveals additional defects involving the RNase H function. Nucleic Acids Res
34: 2853-2863
[Abstract]
[Full Text]
-
Ambrose, Z., Julias, J. G., Boyer, P. L., KewalRamani, V. N., Hughes, S. H.
(2006). The Level of Reverse Transcriptase (RT) in Human Immunodeficiency Virus Type 1 Particles Affects Susceptibility to Nonnucleoside RT Inhibitors but Not to Lamivudine. J. Virol.
80: 2578-2581
[Abstract]
[Full Text]
-
Abram, M. E., Parniak, M. A.
(2005). Virion Instability of Human Immunodeficiency Virus Type 1 Reverse Transcriptase (RT) Mutated in the Protease Cleavage Site between RT p51 and the RT RNase H Domain. J. Virol.
79: 11952-11961
[Abstract]
[Full Text]
-
Gurer, C., Hoglund, A., Hoglund, S., Luban, J.
(2005). ATP{gamma}S Disrupts Human Immunodeficiency Virus Type 1 Virion Core Integrity. J. Virol.
79: 5557-5567
[Abstract]
[Full Text]
-
Nikolenko, G. N., Palmer, S., Maldarelli, F., Mellors, J. W., Coffin, J. M., Pathak, V. K.
(2005). Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: Balance between RNase H activity and nucleotide excision. Proc. Natl. Acad. Sci. USA
102: 2093-2098
[Abstract]
[Full Text]
-
Morcock, D. R., Thomas, J. A., Gagliardi, T. D., Gorelick, R. J., Roser, J. D., Chertova, E. N., Bess, J. W. Jr., Ott, D. E., Sattentau, Q. J., Frank, I., Pope, M., Lifson, J. D., Henderson, L. E., Crise, B. J.
(2005). Elimination of Retroviral Infectivity by N-Ethylmaleimide with Preservation of Functional Envelope Glycoproteins. J. Virol.
79: 1533-1542
[Abstract]
[Full Text]
-
Ambrose, Z., Boltz, V., Palmer, S., Coffin, J. M., Hughes, S. H., KewalRamani, V. N.
(2004). In Vitro Characterization of a Simian Immunodeficiency Virus-Human Immunodeficiency Virus (HIV) Chimera Expressing HIV Type 1 Reverse Transcriptase To Study Antiviral Resistance in Pigtail Macaques. J. Virol.
78: 13553-13561
[Abstract]
[Full Text]
-
Lu, R., Limon, A., Devroe, E., Silver, P. A., Cherepanov, P., Engelman, A.
(2004). Class II Integrase Mutants with Changes in Putative Nuclear Localization Signals Are Primarily Blocked at a Postnuclear Entry Step of Human Immunodeficiency Virus Type 1 Replication. J. Virol.
78: 12735-12746
[Abstract]
[Full Text]
-
Julias, J. G., McWilliams, M. J., Sarafianos, S. G., Alvord, W. G., Arnold, E., Hughes, S. H.
(2004). Effects of Mutations in the G Tract of the Human Immunodeficiency Virus Type 1 Polypurine Tract on Virus Replication and RNase H Cleavage. J. Virol.
78: 13315-13324
[Abstract]
[Full Text]
-
Baumann, J. G., Unutmaz, D., Miller, M. D., Breun, S. K. J., Grill, S. M., Mirro, J., Littman, D. R., Rein, A., KewalRamani, V. N.
(2004). Murine T Cells Potently Restrict Human Immunodeficiency Virus Infection. J. Virol.
78: 12537-12547
[Abstract]
[Full Text]
-
Boyer, P. L., Stenbak, C. R., Clark, P. K., Linial, M. L., Hughes, S. H.
(2004). Characterization of the Polymerase and RNase H Activities of Human Foamy Virus Reverse Transcriptase. J. Virol.
78: 6112-6121
[Abstract]
[Full Text]
-
Zhang, X.-Y., La Russa, V. F., Reiser, J.
(2004). Transduction of Bone-Marrow-Derived Mesenchymal Stem Cells by Using Lentivirus Vectors Pseudotyped with Modified RD114 Envelope Glycoproteins. J. Virol.
78: 1219-1229
[Abstract]
[Full Text]
-
McWilliams, M. J., Julias, J. G., Sarafianos, S. G., Alvord, W. G., Arnold, E., Hughes, S. H.
(2003). Mutations in the 5' End of the Human Immunodeficiency Virus Type 1 Polypurine Tract Affect RNase H Cleavage Specificity and Virus Titer. J. Virol.
77: 11150-11157
[Abstract]
[Full Text]
-
Rausch, J. W., Qu, J., Yi-Brunozzi, H. Y., Kool, E. T., Le Grice, S. F. J.
(2003). Hydrolysis of RNA/DNA hybrids containing nonpolar pyrimidine isosteres defines regions essential for HIV type 1 polypurine tract selection. Proc. Natl. Acad. Sci. USA
100: 11279-11284
[Abstract]
[Full Text]
-
Julias, J. G., McWilliams, M. J., Sarafianos, S. G., Alvord, W. G., Arnold, E., Hughes, S. H.
(2003). Mutation of Amino Acids in the Connection Domain of Human Immunodeficiency Virus Type 1 Reverse Transcriptase That Contact the Template-Primer Affects RNase H Activity. J. Virol.
77: 8548-8554
[Abstract]
[Full Text]
-
Balakrishnan, M., Roques, B. P., Fay, P. J., Bambara, R. A.
(2003). Template Dimerization Promotes an Acceptor Invasion-Induced Transfer Mechanism during Human Immunodeficiency Virus Type 1 Minus-Strand Synthesis. J. Virol.
77: 4710-4721
[Abstract]
[Full Text]
-
Buckman, J. S., Bosche, W. J., Gorelick, R. J.
(2002). Human Immunodeficiency Virus Type 1 Nucleocapsid Zn2+ Fingers Are Required for Efficient Reverse Transcription, Initial Integration Processes, and Protection of Newly Synthesized Viral DNA. J. Virol.
77: 1469-1480
[Abstract]
[Full Text]
-
Limon, A., Nakajima, N., Lu, R., Ghory, H. Z., Engelman, A.
(2002). Wild-Type Levels of Nuclear Localization and Human Immunodeficiency Virus Type 1 Replication in the Absence of the Central DNA Flap. J. Virol.
76: 12078-12086
[Abstract]
[Full Text]
-
Limon, A., Devroe, E., Lu, R., Ghory, H. Z., Silver, P. A., Engelman, A.
(2002). Nuclear Localization of Human Immunodeficiency Virus Type 1 Preintegration Complexes (PICs): V165A and R166A Are Pleiotropic Integrase Mutants Primarily Defective for Integration, Not PIC Nuclear Import. J. Virol.
76: 10598-10607
[Abstract]
[Full Text]
-
Seamon, J. A., Jones, K. S., Miller, C., Roth, M. J.
(2002). Inserting a Nuclear Targeting Signal into a Replication-Competent Moloney Murine Leukemia Virus Affects Viral Export and Is Not Sufficient for Cell Cycle-Independent Infection. J. Virol.
76: 8475-8484
[Abstract]
[Full Text]
-
Julias, J. G., McWilliams, M. J., Sarafianos, S. G., Arnold, E., Hughes, S. H.
(2002). Mutations in the RNase H domain of HIV-1 reverse transcriptase affect the initiation of DNA synthesis and the specificity of RNase H cleavage in vivo. Proc. Natl. Acad. Sci. USA
99: 9515-9520
[Abstract]
[Full Text]
-
Rinke, C. S., Boyer, P. L., Sullivan, M. D., Hughes, S. H., Linial, M. L.
(2002). Mutation of the Catalytic Domain of the Foamy Virus Reverse Transcriptase Leads to Loss of Processivity and Infectivity. J. Virol.
76: 7560-7570
[Abstract]
[Full Text]
-
Brincat, J. L., Pfeiffer, J. K., Telesnitsky, A.
(2002). RNase H Activity Is Required for High-Frequency Repeat Deletion during Moloney Murine Leukemia Virus Replication. J. Virol.
76: 88-95
[Abstract]
[Full Text]